Please Wait...

Expert Biomarker Services For Alzheimer's Disease Research

Alzheimer's Disease (AD), a fatal neurodegenerative disorder characterized by progressive cognitive impairment and memory loss, is the major cause of dementia. The two main neuropathological hallmarks of AD are extracellular amyloid plaques, and neurofibrillary tangles (NTFs), primarily composed of the protein tau.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a normal or pathological process, or as a measure of response to therapy. Application of cerebrospinal fluid-based (CSF) and blood-based biomarkers in clinical research has revolutionized the understanding of AD. Especially, detection of Aβ and tau in CSF has led to crucial advancements in disease detection at its earliest stage (Fig 1).

In general, biomarkers have proven extremely useful throughout the different steps of AD clinical trials: patient inclusion and enrichment, and evaluation of target engagement and clinical efficacy of therapeutic drugs. Changes in CSF and blood-based biomarkers reflect different pathological processes in AD.

Informed Decision-Making. Quality Data. Improved Outcomes.

Bioclinica AD biochemical marker capabilities:

  • Fit-for-Purpose Validation
  • Expertise in Sample Handling
  • Centralized analysis to minimize assay variability
  • Controlled storage of biological samples
  • Established partnership with internationally recognized KOL
  • AD specific Proficiency Testing Program

 

Fluid-based biomarkers can facilitate development of new AD therapies by allowing:

  • Enrichment and stratification of patients
  • Evaluation of target engagment
  • Measurement of disease progression
  • Clinical efficacy and safety assessment of therapeutic drugs

 

Download our AD Biomarker Expertise Sheet

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @scrtrials: Sam Shepard's passing is a reminder of the fight against ALS. 2016 was an important year for discovery. https://t.co/LP5nw0m…
bioclinica (4 days ago)
RT @eClinical_Jen: SCDM White Papers on Mobile Health and eSource by the Leading Data Managment Organization https://t.co/1cG50Lqvj2 #eheal…
bioclinica (5 days ago)
RT @eClinical_Jen: Data Managers - There is a FREE guideline for Good Clinical Data Management Practices here: https://t.co/4g7kF6aGGA #ehe…
bioclinica (5 days ago)
RT @Xtalks: IRT Best Practices: How Companies are Accelerating Timelines While Improving Quality Live webinar with @bioclinica https://t.co…
bioclinica (5 days ago)
Cardiovascular imaging use is growing in non-cardiovascular areas #ClinicalTrials. See where in Tim Crowe's blog… https://t.co/7LvcKCds28
bioclinica (5 days ago)
A quick primer on analyzing risk in business processes by our Director of RTSM Delivery Nick Hargaden https://t.co/WOxLTqCvEk
bioclinica (5 days ago)

Latest Blogs: